What do Canadians think about physician-pharmaceutical industry interactions?

Health Policy

Volumn 112, Issue 3, 2013, Pages 255-263

  Holbrook, Anne ^a,b   Lexchin, Joel ^c   Pullenayegum, Eleanor ^a,b   Campbell, Craig ^d   Marlow, Bernard ^e   Troyan, Sue ^a,b   Weijer, Charles ^f   Blackmer, Jeff ^g   Brazil, Kevin ^a,j   Willison, Don ^a,h,i  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c YORK UNIVERSITY   (Canada)

^d Royal College of Physicians and Surgeons of   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f WESTERN UNIVERSITY   (Canada)

^g CMAJ   (Canada)

^h PUBLIC HEALTH ONTARIO   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

more..

Author keywords

Conflict of interest; Drug policy; Physician pharmaceutical industry interactions; Public opinion survey

Indexed keywords

ADULT; ADVERTIZING; AGED; ARTICLE; CONFLICT OF INTEREST; CONSUMER ATTITUDE; DRUG INDUSTRY; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRESCRIPTION; PUBLIC OPINION; RANDOM DIGIT DIALING; TELEPHONE INTERVIEW;

CONFLICT OF INTEREST; DRUG POLICY; PHYSICIAN-PHARMACEUTICAL INDUSTRY INTERACTIONS; PUBLIC OPINION SURVEY;

ADULT; AGED; CANADA; CONFLICT OF INTEREST; DRUG INDUSTRY; FEMALE; FOCUS GROUPS; HUMANS; MALE; MIDDLE AGED; PHYSICIANS; PUBLIC OPINION; QUESTIONNAIRES;

EID: 84887115720     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2013.04.020     Document Type: Article

References (39)

1. IOM (Institute of Medicine) Conflict of interest in medical research, education, and practice 2009, The National Academies Press, Washington, DC, Available from: http://www.ncbi.nlm.nih.gov/books/NBK22942/pdf/TOC.pdf.
2. Irwin R.S. The role of conflict of interest in reporting of scientific information. CHEST 2009, 136:253-259.
3. Steinbrook R. Controlling conflict of interest - proposals from the institute of medicine. New England Journal of Medicine 2009, 360:2160-2163.
4. Spingarn R.W., Berlin J.A., Strom B.L. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?. Academic Medicine 1996, 71(1):86-88.
5. Campbell E.G., Gruen R.L., Mountford J., Miller L.G., Cleary P.D., Blumenthal D. A national survey of physician-industry relationships. New England Journal of Medicine 2007, 356:1742-1750.
6. Brennan T.A., Rothman D.J., Blank L., Blumenthal D., Chimonas S.C., Cohen J.J., et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006, 295(4):429-433.
7. Spurling G.K., Mansfield P.R., Montgomery B.D., Lexchin J., Doust J., Othman N., et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Medicine 2010, 7(10):e1000352. 10.1371/journal.pmed.
8. Licurse A., Barber E., Joffe S., Gross C. The impact of disclosing financial ties in research and clinical care: a systematic review. Archives of Internal Medicine 2010, 170(8):675-682.
9. Lemmens T., Singer P.A. Bioethics for clinicians: 17. Conflict of interest in research, education and patient care. Canadian Medical Association Journal 1998, 159(8):960-965.
10. Gillon R. Medical ethics: four principles plus attention to scope. British Medical Journal 1994, 309:184.
11. Bowman M.A., Pearle D.L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education in the Health Professions 1988, 8(1):13-20.
12. Caudill T.S., Johnson M.S., Rich E.C., McKinney W.P. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Archives of Family Medicine 1996, 5(4):201-206.
13. Chren M.M., Landefeld C.S. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994, 271(9):684-689.
14. The College of Physicians and Surgeons of Ontario Duties: to the patient 2012, [homepage on internet]. Available from: http://www.cpso.on.ca/policies/guide/default.aspx?id=2018&terms=conflict+of+interest [cited 31.01.12].
15. Canadian Agency for Drugs and Technologies in Health Conflict of interest guidelines for the common drug review. Ottawa 2007, Available from: http://cadth.ca/media/cdr/committees/cedac/cdr_conflict_of_interest_guidelines_e.pdf [cited 30.01.12].
16. College of Family Physicians of Canada By-laws of the college of family physicians of Canada 2012, Available from: http://www.cfpc.ca/uploadedFiles/About_Us/Bylaws/CFPC%20Bylaws%20Ratified%20October%2015%202010.pdf [cited 30.01.12].
17. Canadian Medical Association Guidelines for physicians in interactions with industry. Ottawa 2007, Available from: http://policybase.cma.ca/dbtw-wpd/Policypdf/PD08-01.pdf [cited 30.01.12].
18. Ministry of Health and Long-Term Care Terms of Reference and Administrative Guidelines. The Committee to Evaluate Drugs. Ottawa 2010, Available from: www.ontla.on.ca/library/repository/mon/24004/300672.pdf [cited 31.01.12].
19. Royal College of Physicians and Surgeons of Canada Physicians and industry: conflicts of interest 2005, Royal College of Physicians and Surgeons of Canada, Ottawa, Ontario, Available from: http://rcpsc.medical.org/publications/policy/physicians-industry_e.html [January 2005].
20. Collège des médecins du Québec Legal, ethical and organizational aspects of medical practice in Québec. ALDO-Québec 2010 Edition, Available from: www.cmq.org/en/~/media/486DEE11CEC849318C0135176BE6CA72.ashx [cited 31.01.12].
21. Catton M. Medical schools tackle conflict of interest. Canadian Medical Association Journal 2005, 173:1143.
22. Faculty of health sciences guidelines regarding management of commercial/private sector/government relationships in research and education. Statement on conflict of interest 2009, Faculty of Health Sciences, McMaster University, Hamilton, www.mcmaster.ca/mufa/handbook/Conflict%20of%20Interest%20in%20Research.pdf.
23. Lexchin J., Sekeres M., Gold J., Ferris L.E., Kalkar S.R., Wu W., et al. National evaluation of policies on individual financial conflicts of interest in Canadian Academic Health Science Centers. Journal of General Internal Medicine 2008, 23(11):1896-1903.
24. Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis - learning from the cases of Nancy Olivieri and David Healy. Journal of Medical Ethics 2004, 30(1):8-24.
25. Rochon P.A., Sekeres M., Lexchin J., Moher D., Wu W., Kalkar S.R., Van Laethem M., et al. Institutional financial conflicts of interest policies at Canadian academic health science centres: a national survey. Open Medicine 2010, 4(3):134-138.
26. Rochon P.A., Sekeres M., Hoey J., Lexchin J., Ferris L.E., Moher D., et al. Investigator experiences with financial conflicts of interest in clinical trials. Trials 2011, 12:9.
27. Canada's Research-Based Pharmaceutical Companies (RX&D) Code of ethical practices 2012, Available from: https://www.canadapharma.org/en/commitment/healthcare/documents/2012_CodeofEthicalPractices_ENFinal.pdf.
28. Canada's Research-Based Pharmaceutical Companies Principles & Integrity: Code of Conduct. Ottawa 2008, Available from:. http://www.cag-acg.org/uploads/rx&dcodeofconduct2008.pdf.
29. Wazana A., Primeau F. Ethical considerations in the relationship between physicians and the pharmaceutical industry. Psychiatric Clinics of North America 2002, 25(3):647-663. viii.
30. Peppin J.F. An Engelhardtian analysis of interactions between pharmaceutical sales representatives and physicians. Journal of Medicine and Philosophy 1997, 22(6):623-641.
31. van der Burg W. Bioethics and law: a developmental perspective. Bioethics 1997, 11(2):91-114.
32. Canadian Agency for Drugs and Technologies in Health Call for Public Members - For Canadian Expert Drug Advisory Committee (CEDAC) and Compus Expert Review Committee (CERC) 2012, [homepage on internet]. Available from: http://cadth.ca/en/media-centre/2006/call-for-public-members-for-canadian-expert-drug [cited 30.01.12].
33. Ministry of Health and Long-Term Care Transparent Drug System for Patients Act, 2006 2012, [homepage on internet]. Available from: http://www.health.gov.on.ca/english/public/legislation/drugs/hu_drugsact.html [cited 30.01.12].
34. Ontario Ministry of Health and Long-Term Care Speaking Notes Presented by the Honourable George Smitherman, Deputy Premier and Minister of Health and Long-Term Care, at the Aging at Home Innovations Showcase 2012, Available from: http://www.health.gov.on.ca/en/news/speech/2008/sp_20080423.aspx [cited 30.01.12].
35. Arkinson J., Holbrook A., Wiercioch W. Public perceptions of physician - pharmaceutical industry interactions: a systematic review. Healthc Policy 2010, 5(4):69-89.
36. Statistics Canada 2006 Census of Population, Statistics Canada catalogue no. 97-551-XCB2006009 2006, (Corner Brook, Code015).
37. Statistics Canada CANSIM Table 202-0605 2008, Available from: http://www.statcan.gc.ca/stcsrd/query.html?charset=iso-8859-1&style=eclfst&qm=1&qt=2008&st=126 [retrieved October 2010].
38. Macneill P.U., Kerridge I.H., Newby D., Stokes B.J., Doran E., Henry D.A. Attitudes of physicians and public to pharmaceutical industry 'gifts'. Internal Medicine Journal 2010, 40(5):335-341.
39. Jastifer J., Roberts S. Patients' awareness of and attitudes toward gifts from pharmaceutical companies to physicians. International Journal of Health Services 2009, 39(2):405-414.